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Therapeutic protein products provide unique and effective treatments for numerous human
diseases and medical conditions. In many cases, these treatments are used chronically to
slow disease progression, reduce morbidity and/or to replace essential proteins that are not
produced endogenously in patients. Therefore, any factor that reduces or eliminates the
effectiveness of the treatment can lead to patient suffering and even death. One means by
which efficacy of therapeutic proteins can be compromised is by an immune response,
resulting in antibody-mediated neutralization of the protein’s activity or alterations in
bioavailability.1,2 For example, in the case of treatment of hemophilia A, neutralizing
antibodies to Factor VIII can cause life-threatening bleeding episodes, resulting in
significant morbidity and necessitating treatment with a prolonged course of a tolerance-
inducing therapy to reverse immunity.3,4 In other cases, drug-induced antibodies to a
therapeutic version of an endogenous protein can cross-react with and neutralize the
patient’s endogenous protein. If the endogenous protein serves a non-redundant biological
function, such an immune response can have devastating results. For example, pure red cell
aplasia can result from neutralizing antibodies to epoetin alpha. 1,2
It is well established that protein aggregates in therapeutic protein products can enhance
immunogenicity2, and such an effect is therefore an important risk factor to consider when
assessing product quality. The purpose of this commentary is to accomplish the following:
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i. provide brief summaries on the factors affecting protein aggregation and the key
aspects of protein aggregates that are associated with immunogenicity;
ii. emphasize the current scientific gaps in understanding and analytical limitations for
quantitation of species of large protein aggregates that are referred to as subvisible
particles, with specific consideration of those particles 0.1–10 μm in size;
iii. offer a rationale for why these gaps may compromise the safety and/or efficacy of a
product;
iv. provide scientifically sound, risked based recommendations/conclusions for
assessment and control of such aggregate species.
Causes of Protein Aggregation
Proteins usually aggregate from partially unfolded molecules, which can be part of the
native state ensemble of molecules.5 Even though product formulations are developed to
maximize and maintain the fraction of the protein molecules present in the native state,
significant amounts of aggregates can form, especially over pharmaceutically-relevant time
scales and under stress conditions. For example, exposure to interfaces (e.g., air-liquid and
solid-liquid), light, temperature fluctuations or minor impurities can induce aggregation.
Such exposure can occur during processing steps, as well as in the final product container
during storage, shipment and handling. Furthermore, protein particles (visible and
subvisible) can be generated from protein alone or from heterogeneous nucleation on foreign
micro- and nanoparticles that are shed, for example, from filling pumps or product
container/closures.6–8
The levels and sizes of protein particles present in a given product can be changed by many
factors relevant to commercial production of therapeutic proteins. Such factors include a
change in the type of filling pump during scale-up to commercial manufacturing, changes in
formulation or container/closure, and even unintentional changes in the manufacturing
process such as alterations in filling pump mechanical parameters or other unforeseen
factors.8,9 Thus, unless appropriate quality controls are in place for subvisible particles, a
product that was safe and effective in clinical trials may unexpectedly cause adverse events
in patients after commercialization.
Effects of Aggregate Characteristics on Immunogenicity
From work on fundamental aspects of immunology and vaccine development, it is known
that large protein assemblies with repetitive arrays of antigens, in which the protein
molecules have native conformation, are usually the most potent at inducing immune
responses.2,10,11 Furthermore, efforts to develop more effective vaccines have shown that
adsorbing antigenic proteins to nano- or microparticles comprised of other materials (e.g.,
colloidal aluminum salts or polystyrene) can greatly increase immunogenicity.12,13
Applying these lessons to therapeutic protein products, it has been argued that large
aggregates containing protein molecules with native-like conformation pose the greatest risk
of causing adverse immune responses in patients.2 Thus, for example, particles of
therapeutic proteins formed by adsorption of protein molecules onto foreign micro- and
nanoparticles might be particularly prone to cause immunogenicity. These particles contain
numerous protein molecules, and in the two examples published to date, the adsorbed
protein molecules were shown to retain their native conformations.6,8
Unfortunately, lacking are published studies that comprehensively investigate the range of
parameters that could influence immunogenicity of aggregates. Because each protein may
differ in aggregate formation and consequences, factors that need to be investigated include
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but are not limited to type, amount and size of aggregates, as well as protein conformation in
aggregates, on a case by case basis. Of course, other factors, particularly pertaining to
patient status and treatment protocol, are also critical in determining the propensity to
generate immune responses. These include immune competence of the patients, route of
administration, and dosing frequency and duration. Given the consequences of aggregate-
induced immunogenicity in patients, it is important to understand these issues and to reduce
the risk to product quality for every therapeutic protein product.
Because the exact characteristics and levels of protein aggregates that lead to an enhanced
immune response are unclear and may differ among proteins, it is not possible to predict, a
priori, the in vivo effects of different sizes, types or quantities of aggregates for therapeutic
protein products. In such situations, careful analysis of the relationship between clinical
performance and the presence of protein aggregates in relevant clinical trial material may
help in the design of suitable control strategies that ensure product quality. However, the
validity and utility such correlations are only optimized when the full spectrum of protein
aggregate species are thoroughly characterized by multiple and orthogonal techniques.
Critical Gaps in the Analysis and Control of Subvisible Particles
Protein aggregates that can be quantified based on the mass percentage for each aggregate
size are usually classified as soluble and insoluble. There is mass balance between the
amount of protein in the aggregates and the loss of the monomeric protein. However,
subvisible particles usually do not constitute a sufficient mass fraction of the protein
population to be quantified based on mass of protein in the particles or by loss of monomeric
protein. Typically, these particles are quantified by counting the number of particles in given
size ranges. Subvisible particles are usually defined as particles that are too large for
analysis by size exclusion chromatography (SEC) (e.g., ~ > 0.1 μm), but too small to be
visible to the unaided eye (e.g., < 100 μm). Subvisible protein particles are thus relatively
large assemblies (e.g., 0.1–10 μm) that contain thousands to millions of protein molecules.
Historically, analysis of subvisible (and visible) particles has been required for final product
release testing to mitigate the risk associated with the presence of extraneous particles in
injectable solutions, particularly the risk of blood vessel occlusion for intravenously
administered solutions of small molecule parenteral drug products. Consequently, USP
requirements for the light obscuration test <788>, the standard test for sub-visible particulate
analysis, specifies that particulates >10 μm in size are controlled at or below 6000 particles/
container and particles >25 μm are limited to at or below 600 particles/container Although
ICH quality guidance Q6B states that the requirements set forth by pharmacopoeias
pertaining to analytical procedures and acceptance criteria for particulate matter are
applicable to biotechnological products14, the risks associated with the administration of
large aggregated protein particles were never considered in establishment of the USP light
obscuration test <788>. However, ICH Q6B clearly states that specifications “should focus
on those molecular characteristics found to be useful in ensuring the safety and efficacy of
the product”14 and is potentially applicable to the control of large protein aggregates.
In USP 30 monograph <788>, there is an exclusion of injections intended solely for
intramuscular or subcutaneous administration. This exclusion may be appropriate for the
risk of blood vessel occlusion but would not be appropriate for the risk of immunogenicity.
Since subcutaneous and intramuscular routes are often more immunogenic than intravenous
administration, it is appropriate to consider particulates for all parenterally administered
proteins. The revised harmonized version of <788> published in USP 31 does not contain
this exclusion and thus appears to cover all parenteral routes. However, subvisible particles
less then 10 μm are still not evaluated in the USP test.
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Thus, even though large protein aggregates that are classified as subvisible particles are
potentially the most immunogenic class of protein aggregates, subvisible particles smaller
than 10 μm are not currently monitored and recommendations for such testing for
therapeutic proteins products are lacking. Furthermore, unlike the concern regarding
extraneous particles in small molecule parenteral products, protein particles can accumulate
over time during storage of the final presentation. Subvisible protein particles in the 0.1–10
μm range, as well as protein particles > 10 μm, have the potential to impact the safety and
efficacy of the product over its shelf life, a criteria described in ICH Q6B. As with any
product attribute, the level of control necessary should reflect the potential risk to product
quality and could involve monitoring at release and on stability. Risk-mitigating factors are
important in assessing the impact of a product attribute. For aggregates, such a factor could
be the reversibility of the aggregate under the intended route of administration.
The need for manufacturers of pharmaceutical protein products to evaluate and control this
risk to product quality is underscored by published case studies with therapeutic proteins in
which subvisible particles were measured.8,15,16 For example, during filling pump
operations, it was found that an IgG formed hundreds of thousand of particles per ml in the
1.5–3 μm size range, but less than 1000 particles per ml in the 8–15 μm size range.8 In a
formulation study of a therapeutic cytokine formulated with human serum albumin, more
than 90% of subvisible particles were in the 1–2 μm size range, 7–9% were 2–10 μm and
less 0.01% were larger than 10 μm.15 Similarly, subvisible particle counts in a recombinant
hemoglobin product documented that particles smaller than 10 μm were approximately two
orders of magnitude greater in number than particles larger than 10 μm.16 As demonstrated
by these examples, protein products that contain extremely large numbers of particles
smaller than 10 μm might meet the current USP requirement for subvisible particles. If only
particles > 10 μm were quantified in a given product, there could be gaps in understanding
of important degradation products and in product quality assessment.
Also, there are important technical issues related to counting protein particles, especially
those smaller than 1 μm, which is close to the lower size limit of detection of particle
counting instruments operating by light obscuration or electrical current sensing zones.
Hence, is not clear if the results obtained for the smaller size range of particles (e.g., ≤ 1 μm)
are of sufficient accuracy and precision to allow for method qualification and, more
stringently, validation of the method for use in pharmaceutical quality assurance. Particle
counters that operate by laser light scattering can quantify particles as small as 0.1 μm, but
there have not yet been published studies documenting the utility of these systems for
protein particles. Another alternative method is microflow digital imaging, which can be
used for particles as small as 0.75 μm. For each of these types of instruments, there are
important sample handling issues including: a) the potential requirement for a sample
volume exceeding the unit dose volume (e.g., 1 ml) for a given protein product; b)
interference from air bubbles; c) potential need to dilute a sample; and d) difficulties in
handling high viscosity samples. Furthermore, because protein particles may be translucent
and loosely packed, compendial light obscuration techniques and the other methods may not
work as well to quantify protein particles as they do for particles from extraneous materials.
More research is needed to rigorously assess the capabilities of current instruments to
quantify protein particles as small as 0.1 μm and to develop appropriate low volume
sampling methods. Microscopic techniques such as atomic force microscopy and electron
microscopy may be valuable, but these are low throughput methods and also would need
extensive method validation. Finally, considering these technical issues, using multiple and
orthogonal methods may currently be the most prudent means for evaluating subvisible
particulates.
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1. Subvisible protein particles have the potential to negatively impact clinical
performance to a similar or greater degree than other degradation products, such as
soluble aggregates and chemically modified species that are evaluated and
quantified as part of product characterization and quality assurance programs.
2. Current USP particulate testing is not designed to control the potential risk of large
protein aggregates to impact protein immunogenicity. Analytical methods that can
assess particulate characteristics (including composition, amount and reversibility
of the protein aggregate) are critical for developing scientifically sound approaches
for evaluating and mitigating risk to product quality caused by large protein
aggregates.
3. Pharmaceutical and academic researchers and instrument manufacturers should
work together to help define the quantitative capabilities of current particle
counting instruments for particles as small as 0.1 μm and develop new instruments
as needed.
4. The impact of protein aggregates on immunogenicity needs to be elucidated and
should include studies of the role of protein class, amount of aggregate, size of
aggregates, and protein conformation in aggregates. These investigations should be
published in peer reviewed journals.
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